[{"address1": "451 D Street", "address2": "5th Floor Suite 501", "city": "Boston", "state": "MA", "zip": "02210", "country": "United States", "phone": "857 209 0050", "website": "https://elicio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate is ELI-002, a multivalent lymph node\u0096targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trial to target seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node\u0096targeted AMP peptide vaccine in preclinical studies for the treatment of mutant b-raf murine sarcoma viral oncogene homolog B1-driven cancers; and ELI-008, a multivalent lymph node\u0096targeted AMP peptide vaccine in preclinical studies for use in the treatment of mutated tumor protein p53 expressing cancers. Elicio Therapeutics, Inc. is headquartered in Boston, Massachusetts.", "fullTimeEmployees": 32, "companyOfficers": [{"maxAge": 1, "name": "Mr. Robert T. Connelly", "age": 65, "title": "CEO, President & Director", "yearBorn": 1960, "fiscalYear": 2024, "totalPay": 943020, "exercisedValue": 0, "unexercisedValue": 137562}, {"maxAge": 1, "name": "Dr. Allen Richard Nissenson F.A.S.N., FACP, M.D.", "age": 78, "title": "Founder & Independent Director", "yearBorn": 1947, "fiscalYear": 2024, "totalPay": 48125, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Peter  DeMuth Ph.D.", "age": 38, "title": "Chief Scientific Officer", "yearBorn": 1987, "fiscalYear": 2024, "totalPay": 648600, "exercisedValue": 0, "unexercisedValue": 54705}, {"maxAge": 1, "name": "Dr. Christopher M. Haqq M.D., Ph.D.", "age": 59, "title": "Executive VP, Head of Research & Development and Chief Medical Officer", "yearBorn": 1966, "fiscalYear": 2024, "totalPay": 721087, "exercisedValue": 0, "unexercisedValue": 86025}, {"maxAge": 1, "name": "Dr. Darrell J. Irvine Ph.D.", "title": "Co-Founder, Consultant, Board Observer & Chairman of Scientific Advisory Board", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Preetam  Shah M.B.A., Ph.D.", "age": 53, "title": "Chief Strategy & Financial Officer and Treasurer", "yearBorn": 1972, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Marc J. Wolfgang M.S.", "title": "Chief Technology Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Megan C. Filoon", "title": "General Counsel, Secretary & Compliance Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Esther  Welkowsky", "title": "Senior Vice President of Clinical Development", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Joy  Seymour", "title": "VP & Head of Regulatory Affairs", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 10, "boardRisk": 7, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 9, "governanceEpochDate": 1769904000, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 7.61, "open": 7.75, "dayLow": 7.505, "dayHigh": 8.34, "regularMarketPreviousClose": 7.61, "regularMarketOpen": 7.75, "regularMarketDayLow": 7.505, "regularMarketDayHigh": 8.34, "payoutRatio": 0.0, "beta": 2.157, "forwardPE": -5.5282393, "volume": 115820, "regularMarketVolume": 115820, "averageVolume": 106116, "averageVolume10days": 151330, "averageDailyVolume10Day": 151330, "bid": 8.21, "ask": 8.4, "bidSize": 1, "askSize": 1, "marketCap": 143591984, "fiftyTwoWeekLow": 4.6, "fiftyTwoWeekHigh": 12.62, "allTimeHigh": 263.0, "allTimeLow": 2.96, "fiftyDayAverage": 8.1443, "twoHundredDayAverage": 8.673025, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 139838512, "profitMargins": 0.0, "floatShares": 11791297, "sharesOutstanding": 17258652, "sharesShort": 1158777, "sharesShortPriorMonth": 1156572, "sharesShortPreviousMonthDate": 1765756800, "dateShortInterest": 1768435200, "sharesPercentSharesOut": 0.0671, "heldPercentInsiders": 0.36771, "heldPercentInstitutions": 0.12382, "shortRatio": 12.9, "shortPercentOfFloat": 0.1, "impliedSharesOutstanding": 17258652, "bookValue": 0.221, "priceToBook": 37.647057, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "netIncomeToCommon": -45857000, "trailingEps": -3.11, "forwardEps": -1.505, "lastSplitFactor": "1:10", "lastSplitDate": 1685664000, "enterpriseToEbitda": -3.321, "52WeekChange": -0.05933249, "SandP52WeekChange": 0.120657206, "quoteType": "EQUITY", "currentPrice": 8.32, "targetHighPrice": 18.0, "targetLowPrice": 13.0, "targetMeanPrice": 15.5, "targetMedianPrice": 15.5, "recommendationMean": 1.0, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 2, "totalCash": 20611000, "totalCashPerShare": 1.179, "ebitda": -42108000, "totalDebt": 15057000, "quickRatio": 3.164, "currentRatio": 3.295, "debtToEquity": 394.575, "returnOnAssets": -0.79396003, "freeCashflow": -22453250, "operatingCashflow": -38899000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "ELTX", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "Elicio Therapeutics, Inc.", "longName": "Elicio Therapeutics, Inc.", "marketState": "CLOSED", "corporateActions": [], "postMarketTime": 1770411863, "regularMarketTime": 1770411603, "exchange": "NCM", "messageBoardId": "finmb_214936128", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": 9.32982, "regularMarketPrice": 8.32, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1612535400000, "postMarketChangePercent": 0.0, "postMarketPrice": 8.32, "postMarketChange": 0.0, "regularMarketChange": 0.71, "regularMarketDayRange": "7.505 - 8.34", "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 106116, "fiftyTwoWeekLowChange": 3.7199998, "fiftyTwoWeekLowChangePercent": 0.8086956, "fiftyTwoWeekRange": "4.6 - 12.62", "fiftyTwoWeekHighChange": -4.3, "fiftyTwoWeekHighChangePercent": -0.34072903, "fiftyTwoWeekChangePercent": -5.933249, "earningsTimestampStart": 1754942400, "earningsTimestampEnd": 1755288000, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -3.11, "epsForward": -1.505, "epsCurrentYear": -2.505, "priceEpsCurrentYear": -3.321357, "fiftyDayAverageChange": 0.17569923, "fiftyDayAverageChangePercent": 0.021573275, "twoHundredDayAverageChange": -0.35302544, "twoHundredDayAverageChangePercent": -0.04070384, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "prevName": "Angion Biomedica Corp.", "nameChangeDate": "2026-02-06", "averageAnalystRating": "1.0 - Strong Buy", "cryptoTradeable": false, "displayName": "Elicio Therapeutics", "trailingPegRatio": null, "__fetch_time": "2026-02-07"}]